Education
School ¡X Major ¡X Degree | Duration |
---|---|
°ª¶¯Âå¾Ç°| ¡X Âå¾Ç¬ã¨s©Ò(²¦) ¡X ³Õ¤h Doctorate, Graduate Institute of Medicine, Kaohsiung Medical College |
1989/09 ¡X 1994/06 |
°ª¶¯Âå¾Ç°| ¡X Âå¾Ç¬ã¨s©Ò(²¦) ¡X ºÓ¤h Master, Graduate Institute of Medicine, Kaohsiung Medical College |
1987/09 ¡X 1989/06 |
°ª¶¯Âå¾Ç°| ¡X ÃľǨt(²¦) ¡X ¾Ç¤h Bachelor, School of Pharmacy, Kaohsiung Medical College |
1983/09 ¡X 1987/06 |
Intramural Experience
Office/Department/Institute | Position | Duration |
---|---|---|
±Ð°È³B Office of Academic Affairs | Associate Vice President for Academic Affairs | 2024/08/01 ¡X 2025/07/31 |
¤ÑµMÃĪ«¬ã¨s©Ò Graduate Institute of Natural Products | Professor | 2009/08/01 ¡X 2009/08/01 |
ÃIJz¾Ç¬ì Department of Pharmacology | Professor | 2009/08/01 ¡X |
ÃIJz¾Ç¬ì Department of Pharmacology | Professor | 2007/08/01 ¡X 2009/07/31 |
ÃIJz¾Ç¬ã¨s©Ò Graduate Institute of Pharmacology | Associate Professor | 2005/11/24 ¡X 2005/07/31 |
ÃIJz¾Ç¬ã¨s©Ò Graduate Institute of Pharmacology | Professor | 2005/08/01 ¡X 2007/07/31 |
ÃIJz¾Ç Pharmacology | Associate Professor | 1998/08/01 ¡X 2005/11/23 |
ÃIJz¾Ç Pharmacology | Lecturer | 1989/08/01 ¡X 1998/07/31 |
Extramural Experience
Discipline
NO | Discipline | Expertise |
---|---|---|
1 | ¥Íª«Âå¹AÃþ Biology, Medicine and Agriculture | ÃIJz¤Î¬r²z Pharmacology and Toxicology |
2 | ¥Íª«Âå¹AÃþ Biology, Medicine and Agriculture | ÃľǤΤ¤ÂåÃÄ Pharmacy and Chinese Medicine and Pharmacy |
Research & Technology Platform Open to the Outside
Interested Area(s)for Interdisciplinary Research
¤ßŦ¦åºÞ¯e¯f¤Î¨äÃĪ«¬ãµo¡Bµ°ª¬°Ê¯ßµw¤Æ¤§¾÷Âà¤Î¨äÃĪ«¬ãµo¡B§Üµoª¢ÃĪ«¤Î¨ä¾÷Âà±´°Q
Cardiovascular pharmacology; Inflammation and bone pharmacology; Drug development in myocardial ischemia-reperfusion, atherosclerosis and restenosis; Traditional Chinese (Herbal) Medicine
Area(s) of Expertise & Research
¤ßŦ¦åºÞÃIJz¾Ç¡B¤ßŦ¯Ê¦å¯Ê®ñ¬ã¨s¡B§Ü¦åºÞ¼W¥Í¡B¦åºÞ½F¬ã¨s¡B§Ü°©ÃPÃĪ«¬ã¨s¡B¤¤¯óÃÄÃIJz¬ã¨s¡B¤ß¦Ù±ð¶ë»P¤ß¦ÙªÎ«p¤§ÃĪ«¬ãµo¡BªvÀøµ°ª¬°Ê¯ßµw¤Æ»P¦åºÞ½F¤§ÃĪ«¬ãµo¡B§Ü¦åºÞ²ÓM¼W¥ÍÃĪ«¤§¬ã¨s ªvÀø¤ßŦ¦åºÞ¯e¯f¤§¤¤¯óÃĪ«¬ã¨s ¼vÅT°©Àf¤§ÃĪ«¬ãµo
Cardiovascular pharmacology Drug development in atherosclerosis and restenosis Drug development in myocardial ischemia-reperfusion Inflammation and bone pharmacology
Publication
NO | Publication |
---|---|
1 | ¯ùÆPl¥Íª«KMUP-3³z¹LPI3K/Akt/eNOS¼W±j¦Û¾½§@¥ÎÀu¤Æ¤ß¦Ù²ÓM«OÅ@ Optimizing myocardial cell protection with xanthine derivative KMUP-3 potentiates autophagy through the PI3K/Akt/eNOS axis. |
2 | ³J¥Õ酶Åé§í¨î¾¯bortezomibªý¤îªÍ°Ê¯ß¥·Æ¦Ù²ÓMªº¼W¥Í©M¾E²¾ Proteasome inhibitor bortezomib prevents proliferation and migration of pulmonary arterial smooth muscle cells |
3 | ¶ÀáIËïl¥Íª« KMUP-1 §í¨î§C®ñ»¤¾É TRPC1 ªí²{¤Î¶t¦À½Õ±±¶tÂ÷¤l¬y¦bªÍ°Ê¯ß¦åºÞ¥·Æ¦Ù²ÓM The Xanthine Derivative KMUP-1 Inhibits Hypoxia-Induced TRPC1 Expression and Store-Operated Ca Entry in Pulmonary Arterial Smooth Muscle Cells. |
4 | ¸¯®Ú¯À¦b°±¸g«á¤ßŦ«OÅ@¤¤ªº§Üª¢©M§Ü®ñ¤Æ§@¥Î¡GAkt ©M¦å¬õ¯À¥[®ñ酶-1 ªº¨¤¦â Anti-Inflammatory and Anti-oxidative Effects of Puerarin in Postmenopausal Cardioprotection: Roles of Akt and Heme Oxygenase-1. |
5 | Autologous Fat Grafting in Female Genital Area Improves Sexual Function by Increasing Collagenesis, Angiogenesis, and Estrogen Receptors. Autologous Fat Grafting in Female Genital Area Improves Sexual Function by Increasing Collagenesis, Angiogenesis, and Estrogen Receptors. |
6 | ¶ÀáIËïl¥Íª« KMUP-1 ¥i§ïµ½µøºô½¤¯fÅÜ Xanthine derivative KMUP-1 ameliorates retinopathy. |
7 | ¥i·»©Ê CD93 ¾®¶°¯À¼Ëµ²ºc°ì¹jÂ÷ HMGB1 ¥H§ïµ½ª¢¯g©Ê¯e¯f Soluble CD93 lectin-like domain sequesters HMGB1 to ameliorate inflammatory diseases |
8 | ¶ÀÍÁ¯À³z¹L§í¨îµoª¢©M®ñ¤ÆÀ£¤O¹ï¦åºÞºò±i¯À II ª`¤Jªº¸¡¥D°Ê¯ß½F¨ã¦³¦åºÞ«OÅ@§@¥Î Vasculoprotective Potential of Baicalein in Angiotensin II-Infused Abdominal Aortic Aneurysms through Inhibiting Inflammation and Oxidative Stress |
9 | YULINK¦bªÍ°Ê¯ß¥·Æ¦Ù²ÓM¾E²¾¡B¼W¥Í©M¿}¸Ñ§@¥Î¤¤ªº·s§@¥Î¡G¹ïªÍ°Ê¯ß°ªÀ£ªº¼vÅT The novel roles of YULINK in the migration, proliferation and glycolysis of pulmonary arterial smooth muscle cells: implications for pulmonary arterial hypertension |
10 | ¶ÀáIËïl¥Íª«KMUP-1´î½w¹êÅç©Ê¤ú©Pª¢¸g¥Ñ´î¤Ö¾½°©²ÓM¤À¤Æ»Pµoª¢§@¥Î Xanthine derivative KMUP-1 attenuates experimental periodontitis by reducing osteoclast differentiation and inflammation |
11 | ¶ÀÍÁ¯À¦bÅé¥~©MÅ餺¹w¨¾¥·Æ¦Ù²ÓM¦åºÞ¶t¤Æªº¼ç¦b§@¥Î Potential actions of baicalein for preventing vascular calcification of smooth muscle cells in vitro and in vivo |
12 | Clinical Patterns of Traditional Chinese Medicine for Ischemic Heart Disease Treatment: A Population-Based Cohort Study Clinical Patterns of Traditional Chinese Medicine for Ischemic Heart Disease Treatment: A Population-Based Cohort Study |
13 | ªÍªù¯ß°ªÀ£Á{§É«e¼Ð¹vªvÀø¤§±´°Q The Potential Application and Promising Role of Targeted Therapy in Pulmonary Arterial Hypertension |
14 | °Ê¯ß¾ÉºÞ«¶ìªº¼ç¦b¤À¤l¾÷¨î¡G¶W¶V«e¦C¸¢¯À Molecular Mechanisms Underlying Remodeling of Ductus Arteriosus: Looking Beyond the Prostaglandin Pathway |
15 | ¦åºÞºò±i¯ÀÂà´«酶2¿E¬¡¾¯¥i´î»´¥ªªÍ¤Á°£»PVEGF§í¨îªº¤j¹«¼Ò«¬¤¤ªºÄY«ªÍ°Ê¯ß°ªÀ£ Angiotensin-Converting Enzyme 2 Activator Ameliorates Severe Pulmonary Hypertension in a Rat Model of Left Pneumonectomy Combined With VEGF Inhibition |
16 | KMUP-1«ì´_©PÃ䯫¸g·l¶Ë»¤µoI®Ú¯«¸g¸`BKCa ³q¹D§í¨î§@¥Î BKCa channel inhibition by peripheral nerve injury is restored by the xanthine derivative KMUP-1 in dorsal root ganglia |
17 | In Vitro Evaluation of the Anti-Inflammatory Effect of KMUP-1 and In Vivo Analysis of Its Therapeutic Potential in Osteoarthritis In Vitro Evaluation of the Anti-Inflammatory Effect of KMUP-1 and In Vivo Analysis of Its Therapeutic Potential in Osteoarthritis |
18 | Cinaciguat ³q¹L¦åºÞµÎ±i©M§Ü«¶ì¹w¨¾·s¥Í¤j¹«¥X¥Í«á°Ê¯ß¾ÉºÞÃö³¬ Cinaciguat Prevents Postnatal Closure of Ductus Arteriosus by Vasodilation and Anti-remodeling in Neonatal Rats |
19 | Loganin ¹w¨¾ CXCL12/CXCR4 ½Õ±±¯«¸g©Ê¯kµh³z¹L NLRP3µoª¢Åé¦b¯«¸g·l¶Ëªº¤j¹« Loganin prevents CXCL12/CXCR4-regulated neuropathic pain via the NLRP3 inflammasome axis in nerve-injured rats. |
20 | Loganin ¹w¨¾ºC©Ê¯«¸gÀ£¢·l¶Ë¤Þµo¯«¸g©Ê¯kµh³z¹L°§C TNF-£\/IL-1£] »¤µoNF-£eB ¬¡¤Æ¤Î³\©ô²ÓM¤§¥hÅèÀT¤Æ Loganin prevents chronic constriction injury-provoked neuropathic pain by reducing TNF-£\/IL-1£]-mediated NF-£eB activation and Schwann cell demyelination |
21 | Targeting vascular smooth muscle cell dysfunction with xanthine derivative KMUP-3 inhibits abdominal aortic aneurysm in mice Targeting vascular smooth muscle cell dysfunction with xanthine derivative KMUP-3 inhibits abdominal aortic aneurysm in mice |
22 | Data supporting the effects of xanthine derivative KMUP-3 on vascular smooth muscle cell calcification and abdominal aortic aneurysm in mice. Data supporting the effects of xanthine derivative KMUP-3 on vascular smooth muscle cell calcification and abdominal aortic aneurysm in mice. |
23 | Extracellular heat shock protein HSC70 protects against lipopolysaccharide-induced hypertrophic responses in rat cardiomyocytes Extracellular heat shock protein HSC70 protects against lipopolysaccharide-induced hypertrophic responses in rat cardiomyocytes |
24 | Role of Extracellular Matrix in Pathophysiology of Patent Ductus Arteriosus: Emphasis on Vascular Remodeling Role of Extracellular Matrix in Pathophysiology of Patent Ductus Arteriosus: Emphasis on Vascular Remodeling |
25 | Vasculoprotective effects of Centella asiatica, Justicia gendarussa and Imperata cylindrica decoction via the NOXs-ROS-NF-£eB pathway in spontaneously hypertensive rats Vasculoprotective effects of Centella asiatica, Justicia gendarussa and Imperata cylindrica decoction via the NOXs-ROS-NF-£eB pathway in spontaneously hypertensive rats |
26 | ¶À»G¾J¨¾¤îºû¥Í¯ÀD3©M¥§¥j¤B»¤¾É¤§¦åºÞ¶t¤Æ The Preventive Effects of Xanthohumol on Vascular Calcification Induced by Vitamin D Plus Nicotine. |
27 | The beneficial effects of angiotensin-converting enzyme II (ACE2) activator in pulmonary hypertension secondary to left ventricular dysfunction. The beneficial effects of angiotensin-converting enzyme II (ACE2) activator in pulmonary hypertension secondary to left ventricular dysfunction. |
28 | Inhibition of Neointima Hyperplasia, Inflammation, and Reactive Oxygen Species in Balloon-Injured Arteries by HVJ Envelope Vector-Mediated Delivery of Superoxide Dismutase Gene Inhibition of Neointima Hyperplasia, Inflammation, and Reactive Oxygen Species in Balloon-Injured Arteries by HVJ Envelope Vector-Mediated Delivery of Superoxide Dismutase Gene |
29 | KMUP-1 Ameliorates Ischemia-Induced Cardiomyocyte Apoptosis through the NO-cGMP-MAPK Signaling Pathways KMUP-1 Ameliorates Ischemia-Induced Cardiomyocyte Apoptosis through the NO-cGMP-MAPK Signaling Pathways |
30 | Glucagon-Like Peptide-1 Receptor Agonist Attenuates Autophagy to Ameliorate Pulmonary Arterial Hypertension through Drp1/NOX- and Atg-5/Atg-7/Beclin-1/LC3£] Pathways Glucagon-Like Peptide-1 Receptor Agonist Attenuates Autophagy to Ameliorate Pulmonary Arterial Hypertension through Drp1/NOX- and Atg-5/Atg-7/Beclin-1/LC3£] Pathways |
31 | ¶ÀáIËïl¥ÍKMUP-1¤ÏÂà°ª¿}¬r©Ê¬¡¤Æ¤§Kv³q¹D¸g¥ÑcAMP/PKA°T®§¸ô®|©ó¤j¹«¯Ø®q¤A«¬²ÓM Xanthine-derived KMUP-1 reverses glucotoxicity-activated Kv channels through the cAMP/PKA signaling pathway in rat pancreatic £] cells |
32 | Molecular Mechanisms for Regulating Postnatal Ductus Arteriosus Closure Molecular Mechanisms for Regulating Postnatal Ductus Arteriosus Closure |
33 | Exogenous heat shock Cognate protein 70 suppresses LPS-induced inflammation by down-regulating NF-£eB through MAPK and MMP-2/-9 pathways in macrophages Exogenous heat shock Cognate protein 70 suppresses LPS-induced inflammation by down-regulating NF-£eB through MAPK and MMP-2/-9 pathways in macrophages |
34 | B-type natriuretic peptide prevents postnatal closure of ductus arteriosus by both vasodilation and anti-remodeling in neonatal rats B-type natriuretic peptide prevents postnatal closure of ductus arteriosus by both vasodilation and anti-remodeling in neonatal rats |
35 | GPCR ½Õ±±ª«½èKMUP-1´î¤Ö¤T»Ä¥Ìªo¯×»W¿n¥]§tMAPKs/Akt/PPAR£^¤ÎPKA/PKG/HSL°T®§¦b3T3-L1«e¯×ªÕ²ÓM KMUP-1, a GPCR Modulator, Attenuates Triglyceride Accumulation Involved MAPKs/Akt/PPAR£^ and PKA/PKG/HSL Signaling in 3T3-L1 Preadipocytes |
36 | Xanthohumol isolated from Humulus lupulus prevents thrombosis without increased bleeding risk by inhibiting platelet activation and mtDNA release Xanthohumol isolated from Humulus lupulus prevents thrombosis without increased bleeding risk by inhibiting platelet activation and mtDNA release |
37 | Statins Ameliorate Pulmonary Hypertension Secondary to Left Ventricular Dysfunction Through the Rho-Kinase Pathway and NADPH Oxidase Statins Ameliorate Pulmonary Hypertension Secondary to Left Ventricular Dysfunction Through the Rho-Kinase Pathway and NADPH Oxidase |
38 | Indonesian herbal medicine prevents hypertension-induced left ventricular hypertrophy by diminishing NADPH oxidase-dependent oxidative stress Indonesian herbal medicine prevents hypertension-induced left ventricular hypertrophy by diminishing NADPH oxidase-dependent oxidative stress |
39 | Phosphodiesterase inhibitor KMUP-3 displays cardioprotection via protein kinase G and increases cardiac output via G-protein-coupled receptor agonist activity and Ca(2+) sensitization Phosphodiesterase inhibitor KMUP-3 displays cardioprotection via protein kinase G and increases cardiac output via G-protein-coupled receptor agonist activity and Ca(2+) sensitization |
40 | Åè¨t¾®¦å酶½Õ¸`¯ÀÃþ¾®¶°¯À¥\¯à°Ï§í¨î¹°©²ÓM¥Í¦¨§@¥Î»Pµoª¢©Ê°©½è¬y¥¢ Myeloid thrombomodulin lectin-like domain inhibits osteoclastogenesis and inflammatory bone loss |
41 | ¶ÀáIËïl¥Íª«¥iÂǥѬ¡¤Æ¤º¥Ö²ÓM¤@®ñ¤Æ´á¦X酶¥H´î¤Ö¤º¥Ö«eÅX²ÓM¦b¯Ê®ñ±¡ªp¤U©Ò»¤¾Éªº²ÓMä¤`²{¶H Activation of endothelial NO synthase by a xanthine derivative ameliorates hypoxia-induced apoptosis in endothelial progenitor cells. |
42 | Gamma-secretase Inhibitor Prevents Proliferation and Migration of Ductus Arteriosus Smooth Muscle Cells through the Notch3-HES1/2/5 Pathway Gamma-secretase Inhibitor Prevents Proliferation and Migration of Ductus Arteriosus Smooth Muscle Cells through the Notch3-HES1/2/5 Pathway |
43 | Liraglutide prevents and reverses monocrotaline-induced pulmonary arterial hypertension by suppressing ET-1 and enhancing eNOS/sGC/PKG pathways Liraglutide prevents and reverses monocrotaline-induced pulmonary arterial hypertension by suppressing ET-1 and enhancing eNOS/sGC/PKG pathways |
44 | Metformin Uniquely Prevents Thrombosis by Inhibiting Platelet Activation and mtDNA Release Metformin Uniquely Prevents Thrombosis by Inhibiting Platelet Activation and mtDNA Release |
45 | 3«×¿S¶Ë¤Þµo¯áÅ踡¨¤¹B°Ê¯«¸g¤¸²ÓMä¤`, §¤°©¯«¸g¤Î¦Ù¦×µäÁY Third-Degree Hindpaw Burn Injury Induced Apoptosis of Lumbar Spinal Cord Ventral Horn Motor Neurons and Sciatic Nerve and Muscle Atrophy in Rats |
46 | Xanthine l¥Íª« KMUP-1 ´î®z Serotonin ¤Þ°_ªÍ°Ê¯ß¦åºÞ¯U¯¶¤Î¹[Â÷¤l³q¹D§í¨î¬¡©Ê³z¹L PKC ¸ô®| The Xanthine Derivative KMUP-1 Attenuates Serotonin-Induced Vasoconstriction and K+-Channel Inhibitory Activity via the PKC Pathway in Pulmonary Arteries |
47 | Autologous adipose-derived stem cells attenuate muscular atrophy and protect spinal cord ventral horn motor neurons in an animal model of burn injury. Autologous adipose-derived stem cells attenuate muscular atrophy and protect spinal cord ventral horn motor neurons in an animal model of burn injury. |
48 | Fat Grafting in Burn Scar Alleviates Neuropathic Pain via Anti-Inflammation Effect in Scar and Spinal Cord. Fat Grafting in Burn Scar Alleviates Neuropathic Pain via Anti-Inflammation Effect in Scar and Spinal Cord. |
49 | KMUP-1 Attenuates Endothelin-1-Induced Cardiomyocyte Hypertrophy through Activation of Heme Oxygenase-1 and Suppression of the Akt/GSK-3£], Calcineurin/NFATc4 and RhoA/ROCK Pathways KMUP-1 Attenuates Endothelin-1-Induced Cardiomyocyte Hypertrophy through Activation of Heme Oxygenase-1 and Suppression of the Akt/GSK-3£], Calcineurin/NFATc4 and RhoA/ROCK Pathways |
50 | KMUP-1 Promotes Osteoblast Differentiation Through cAMP and cGMP Pathways and Signaling of BMP-2/Smad1/5/8 and Wnt/£]-Catenin KMUP-1 Promotes Osteoblast Differentiation Through cAMP and cGMP Pathways and Signaling of BMP-2/Smad1/5/8 and Wnt/£]-Catenin |
51 | Cyclic guanosine monophosphate-enhancing reduces androgenic extracellular regulated protein kinases-phosphorylation/Rho kinase II-activation in benign prostate hyperplasia Cyclic guanosine monophosphate-enhancing reduces androgenic extracellular regulated protein kinases-phosphorylation/Rho kinase II-activation in benign prostate hyperplasia |
52 | Autologous fat grafting alleviates burn-induced neuropathic pain in rats. Autologous fat grafting alleviates burn-induced neuropathic pain in rats. |
53 | B«¬§Q¶uàÈ肽©óªÍ¦åºÞ¥·Æ¦Ù²ÓM¤§§Ü¼W¥Í»P§Ü¾E±p§@¥Î B-type Natriuretic Peptide Inhibits Angiotensin ¢º-induced Proliferation and Migration of Pulmonary Arterial Smooth Muscle Cells |
54 | Dual ELE/NEP§í¨î¥i§ïµ½¥D°Ê¯ßÁY¯¶ª¬ªp³y¦¨¤ß«Ç¥¢±`¤§µÎ±i¥\¯à¥¢±`¤Î¤ß«Ç¦A¼Ò¤Æ Dual ELE/NEP inhibition improved diastolic function and ameliorated cardiac remodeling in rats with myocardial dysfunction secondary to pressure overload by aortic banding |
55 | Baicalein Inhibits HMGB1 Release and MMP-2/-9 Expression in Lipopolysaccharide-Induced Cardiac Hypertrophy Baicalein Inhibits HMGB1 Release and MMP-2/-9 Expression in Lipopolysaccharide-Induced Cardiac Hypertrophy |
56 | Baicalein, an active component of Scutellaria baicalensis Georgi, prevents lysophosphatidylcholine-induced cardiac injury by reducing reactive oxygen species production, calcium overload and apoptosis via MAPK pathways. Baicalein, an active component of Scutellaria baicalensis Georgi, prevents lysophosphatidylcholine-induced cardiac injury by reducing reactive oxygen species production, calcium overload and apoptosis via MAPK pathways. |
57 | Exogenous heat shock cognate protein 70 pretreatment attenuates cardiac and hepatic dysfunction with associated anti-inflammatory responses in experimental septic shock. Exogenous heat shock cognate protein 70 pretreatment attenuates cardiac and hepatic dysfunction with associated anti-inflammatory responses in experimental septic shock. |
58 | ¤º¥Ö¤@®ñ¤Æ´á¦X¦¨酶«P¶iG³J¥Õµ²¦X¨üÅé«ú§Ü¾¯§í¨îªÍ°Ê¯ß°ª¦åÀ£¦b³¥¦Ê²üÆP¼Ò¦¡¬OÂÇ¥ÑET-1¬ÛÃö¤ÎET-1¤£¬ÛÃöªº¸ô¶i Endothelial nitric oxide synthase-enhancing G-protein coupled receptor antagonist inhibits pulmonary artery hypertension by endothelin-1-dependent and endothelin-1-independent pathways in a monocrotaline model. |
59 | No donor KMUP-1 improves hepatic ischemia-reperfusion and hypoxic cell injury by inhibiting oxidative stress and pro-inflammatory signaling. No donor KMUP-1 improves hepatic ischemia-reperfusion and hypoxic cell injury by inhibiting oxidative stress and pro-inflammatory signaling. |
60 | Lercanidipine and labedipinedilol-A attenuate lipopolysaccharide/interferon-£^-induced inflammation in rat vascular smooth muscle cells through inhibition of HMGB1 release and MMP-2, 9 activities Lercanidipine and labedipinedilol-A attenuate lipopolysaccharide/interferon-£^-induced inflammation in rat vascular smooth muscle cells through inhibition of HMGB1 release and MMP-2, 9 activities |
61 | KMUP-1 Suppresses RANKL-Induced Osteoclastogenesis and Prevents Ovariectomy-Induced Bone Loss: Roles of MAPKs, Akt, NF-£eB and Calcium/Calcineurin/NFATc1 Pathways KMUP-1 Suppresses RANKL-Induced Osteoclastogenesis and Prevents Ovariectomy-Induced Bone Loss: Roles of MAPKs, Akt, NF-£eB and Calcium/Calcineurin/NFATc1 Pathways |
62 | ¤T¶ÀÂm¤ß´ö«OÅ@¤ßŦ§Ü¯Ê®ñ¦Aµ¹®ñ¶Ë®`¬O¸g¥Ñ§í¨î®ñ¤ÆÀ£¤O¤Þ°_²ÓMµ{¦¡ä¤` San-Huang-Xie-Xin-Tang protects cardiomyocytes against hypoxia/reoxygenation injury via inhibition of oxidative stress-induced apoptosis |
63 | KMUP-1 inhibits hypertension-induced left ventricular hypertrophy through regulation of nitric oxide synthases, ERK1/2, and calcineurin. KMUP-1 inhibits hypertension-induced left ventricular hypertrophy through regulation of nitric oxide synthases, ERK1/2, and calcineurin |
64 | Attenuation of pulmonary hypertension secondary to left ventricular dysfunction in the rat by Rho-kinase inhibitor fasudil Attenuation of pulmonary hypertension secondary to left ventricular dysfunction in the rat by Rho-kinase inhibitor fasudil |
65 | KMUP-3 attenuates ventricular remodelling after myocardial infarction through eNOS enhancement and restoration of MMP-9/TIMP-1 balance KMUP-3 attenuates ventricular remodelling after myocardial infarction through eNOS enhancement and restoration of MMP-9/TIMP-1 balance |
66 | Labedipinedilol-A prevents lysophosphatidylcholine-induced vascular smooth muscle cell death through reducing reactive oxygen species production and anti-apoptosis Labedipinedilol-A prevents lysophosphatidylcholine-induced vascular smooth muscle cell death through reducing reactive oxygen species production and anti-apoptosis |
67 | Eugenolol and glyceryl-isoeugenol suppress LPS-induced iNOS expression by down-regulating NF-kB and AP-1 through inhibition of MAPKs and Akt/IkBa signaling pathways in macrophages Eugenolol and glyceryl-isoeugenol suppress LPS-induced iNOS expression by down-regulating NF-kB and AP-1 through inhibition of MAPKs and Akt/IkBa signaling pathways in macrophages |
68 | Labedipinedilol-A prevents lysophosphatidylcholine-induced vascular smooth muscle cell death through reducing reactive oxygen species production and anti-apoptosis Labedipinedilol-A prevents lysophosphatidylcholine-induced vascular smooth muscle cell death through reducing reactive oxygen species production and anti-apoptosis |
69 | ¤T¶ÀÂm¤ß´ö¨¾¤î¤j¹«¤ßŦ¸g¯Ê®ñ¦Aµ¹®ñ¤Þ°_¤§²ÓMä¤`¬O¸g¥ÑeNOS©MMAPK¸ô®| San-Huang-Xie-Xin-Tang Prevents Rat Hearts from Ischemia/Reperfusion-Induced Apoptosis through eNOS and MAPK Pathways |
70 | Labedipinedilol-A prevents lysophosphatidylcholine-induced vascular smooth muscle cell death through reducing reactive oxygen species production and anti-apoptosis. Labedipinedilol-A prevents lysophosphatidylcholine-induced vascular smooth muscle cell death through reducing reactive oxygen species production and anti-apoptosis. |
71 | KMUP-1¸g¥ÑNO/cGMP/PKG©MERK1/2/calcineurin A¸ô®|´î§Cisoprenaline»¤¾É¤j¹«ªº¤ß¦ÙªÎ«p KMUP-1 attenuates isoproterenol-induced cardiac hypertrophy in rats through NO/cGMP/PKG and ERK1/2/calcineurin A pathways |
72 | ¯ùÆPl¥Íª«KMUP-1¸g¥ÑNO/cGMP¨Ì¿à©Ê§í¨îRhoA/Rho kinase ªí²{ªvÀøªÍ°ªÀ£ The xanthine derivative KMUP-1 inhibits models of pulmonary artery hypertension via increased NO and cGMP-dependent inhibition of RhoA/Rho kinase |
73 | KMUP-1 ¸g¥Ñ serotonin ¨üÅé/transporter »P NO synthase ¤Î §í¨î RhoA »P AKT/ERK ÁC»Ä¤Æ°§CªÍ°Ê¯ß¼W¥Í KMUP-1 inhibits pulmonary artery proliferation by targeting serotonin receptors/transporter and NO synthase, inactivating RhoA and suppressing AKT/ERK phosphorylation |
74 | Protective effects if a dual endothelin converting enzyme/neutral endopeptidase inhibitor on the development of pulmonary hypertension secondary to cardiac dysfunction in the rat Protective effects if a dual endothelin converting enzyme/neutral endopeptidase inhibitor on the development of pulmonary hypertension secondary to cardiac dysfunction in the rat |
75 | Protective effects of a dual endothelin converting enzyme/neutral endothpeptidase inhibitor on the development of pulmonary hypertension secondary to cardiac dysfunction in the rat Protective effects of a dual endothelin converting enzyme/neutral endothpeptidase inhibitor on the development of pulmonary hypertension secondary to cardiac dysfunction in the rat |
76 | Lercanidipine§í¨î¦åºÞ¥·Æ¦Ù²ÓM¼W¥Í©M·s¥Í¤º¼hªº§Î¦¨¬O¸g¥Ñ´î§C¦Û¥Ñ°ò¤Î¥h¬¡¤ÆRas-ERK1/2°T®§¸ô®| Lercanidipine inhibits vascular smooth muscle cell proliferation and neointimal formation via reducing intracellular reactive oxygen species and inactivating Ras-ERK1/2 signaling |
77 | ¤@Ó¿ï¾Ü©Ê¥Ò¤@«¬µÇ¤W¸¢¯À©Ê¨üÅéªýÂ_¾¯Labedipinedilol-A§í¨îÄáÅ@¸¢Àù²ÓM¼W¥Í¬O¬ÛÃö©ó²ÓM¥Íªø¶g´Á°±¤î©M²ÓMä¤` Inhibition of human prostate cancer cells proliferation by a selective alpha1-adrenoceptor antagonist labedipinedilol-A involves cell cycle arrest and apoptosis |
78 | ²Ä¤T¥N¶tÂ÷¤l«ú§Ü¾¯Zanidip¹ï¦åºÞ¥·Æ¦Ùªº¥Íªø§í¨î§@¥Î Growth inhibitory effects of Zanidip, a third-generation calcium antagonist, on vascular smooth muscle cells |
79 | labedipinedilol-A§í¨î¤j¹«¸£¦åºÞ¥·Æ¦Ù²ÓM¹q¦ì¬ÛÃö©Ê L«¬¶tÂ÷¤l³q¹D²o¯A³J¥Õ¿E–¡C Inhibition of voltage-gated L-type calcium channels by labedipinedilol-A involves protein kinase C in rat cerebrovascular smooth muscle cells |
80 | Isoeugenodilol§í¨î¦åºÞ¥·Æ¦Ù²ÓM¼W¥Í©M®ð²yÂX±i³N·s¥Í¤º¼h¸g¥ÑERK1/2¥h¬¡¤Æ§@¥Î Isoeugenodilol inhibits smooth muscle cell proliferation and neointimal thickening after balloon injury via inactivation of ERK1/2 pathway |
81 | Tc-99m (V) DMSA»P¤HÃþ¦å¼ß³J¥Õ½è§@¥Î¾÷Âध¬ã¨s EVALUATION OF TC-99M (V) DMSA BINDING TO HUMAN PLASMA PROTEINS |
82 | ²Ä3¥N¤G²BÏìÔr«¬¶tÂ÷¤lªýÂ_¾¯Labedipinedilol-A¹ïouabain¤Þ°_¤ß«ß¤£¾ã¤§§@¥Î Effects of labedipinedilol-A, third-generation dihydropyridine-type calcium blocker, on ouabain-induced arrhythmia |
83 | À³¥Î¦h¯¸°g§A±¸Õ¡]MMI¡^¿ï¾Ü¾Ç¤h«áÂå¾Ç¨t¾Ç¥Í Using aMultiple Mini-interview Approach to Select Graduate Entry Medical Students |
84 | Effects of sildenafil on pulmonary hypertension and levels of ET-1, eNOS, and cGMP in aorta-banded rats Effects of sildenafil on pulmonary hypertension and levels of ET-1, eNOS, and cGMP in aorta-banded rats |
85 | Differential change in expression of pulmonary ET-1 and eNOS in rats after chronic left ventricular pressure overload. Differential change in expression of pulmonary ET-1 and eNOS in rats after chronic left ventricular pressure overload. |
86 | ¶ÀáIËïl¥Íª«KMUP-1¤ÎKMUP-3§í¨î¤j¹«®ðºÞ«e,µoª¢ª«½èTNF-a¤Þµo»¤¾É«¬¤@®ñ¤Æ´á酶,Ãö³s©ó·»¸Ñ«¬³¾ÁTáIËïÀô¤Æ酶¤ÎG³J¥Õ¿E酶 Inhibition of Proinflammatory Tumor Necrosis Factor--Induced Inducible Nitric-Oxide Synthase by Xanthine-Based 7-[2-[4- (2-Chlorobenzene)piperazinyl]ethyl]-1,3-dimethylxanthine (KMUP-1) and 7-[2-[4-(4-Nitrobenzene)piperazinyl]ethyl]-1, 3-dimethylxanthine (KMUP-3) in Rat Trachea: The Involvement of Soluble Guanylate Cyclase and Protein Kinase G |
87 | Protective effect of labedipinedilol-A, a novel dihydropyridine-type calcium channel blocker, on myoardial apoptosis in ischemia -- reperfusion injury. Protective effect of labedipinedilol-A, a novel dihydropyridine-type calcium channel blocker, on myoardial apoptosis in ischemia -- reperfusion injury. |
88 | Liberadipinedilol-A¤§¦åºÞÃP¦¢§@¥Î¬ÛÃö¶tÂ÷¤l¤º¬y¤Þµo¤º¥Ö²ÓMl¥Í¤@®ñ¤Æ´á¤Î¨ä¦X¦¨酶ªí²{ The vasorelaxing action of labedipinedilol-A involves endothelial cell-derived NO and eNOS expression caused by calcium influx. |
89 | Åöíw»¤µo²ÓM¤ºGABA A«¬¨üÅé°ï¿n Status epilepticus increases the intracellular accumulation of GABA(A) receptors |
90 | Labedipinedilol C: ²Ä¤T¥Ndihydropyridine«¬¶tÂ÷¤l³q¹D«ú§Ü¾¯¡A§e²{¹[Â÷¤l³q¹D¶}±Ò¡B¤@®ñ¤Æ´á¬ÛÃö»PµÇ¤W¸¢«ú§Ü¬¡©Ê Labedipinedilol-C: a third-generation dihydropyridine-type calcium channel antagonist displaying K+ channel opening, NO-dependent and adrenergic antagonist activities. |
91 | ¦bÄ~µo©Ê¨ì¥ý¤Ñ©Ê¤ßŦ¯fªº¥®¨à»P¤p«Ä·|¼W¥[¦å²G´`Àôªº big endothelin-1¡Bendothelin-1¤Îatrial natriuretic peptide Increased circulating big endothelin-1, endothelin-1 and atrial natriuretic peptide in infants and children with heart failure secondary to congenital heart disease. |
92 | ¦s¦b©óªÍ°Ê¯ß䳬Âê¦X¨Ö§¹¾ã¤ß«Ç¤¤¹jªº¨Ì¿à¥k¤ß«Çªº«aª¬°Ê¯ß´`Àô Increased circulating calcitonin gene-related peptide in congestive heart failure caused by congenital heart disease. |
93 | Vanylidilol: ¤@f¤AîÇ°òµÇ¤W¸¢¯À¿E©Ê¥Ò/¤A«¬ªýÂ_¾¯¨ã¤º¥Ö²ÓM¬ÛÃö»P¥ÒÂ÷¤l³q¹D¶}±Ò¬ÛÃöªº¦åºÞÃP¦¢¬¡©Ê¤§§Ü°ª¦åÀ£§@¥Î Anti-Hypertension Effect of Vanylidilol: A Phenylaldehyde /-Adrenoceptor Blocker with Endothelium-Dependent and K+ Channels Opening-Associated Vasorelaxant Activities |
94 | ¤º¥Ö©Ê¤@®ñ¤Æ´á¦X¦¨»Ã¯À¤Î¤º¥Ö¯À-1¦b¤ß°IºÜ¤Þ°_ªºªÍ°ªÀ£ª¬ªp¤U¦³¤W¤ÉÁÍ¶Õ Upregulation of Endothelial Nitric Oxide Synthase and Endothelin-1 in Pulmonary Hypertension Secondary to Heart Failure in Aorta-Banded Rats |
95 | Labedipinedilol-A ¦b¤j¹«¥·Æ¦Ù²ÓM§í¨î¼W¥Í¬O¸g¥ÑPKC ©M ERK 1/2 ³~®| Inhibition of Mitogen-Mediated Proliferation of Rat Vascular Smooth Muscle Cells by Labedipinedilol-A through PKC and ERK 1/2 Pathway |
96 | µf´Ô´¹¯Àl¥Íª«VOA¸g¥ÑCGRP, NO, cGMP¤Î¦åºÞ¤º¥Ö¬ÛÃö§@¥Î¤Þ°_¤j¥Õ¹«¸zô½¤°Ê¯ß¤Î¥D°Ê¯ß¤§ÃP¦¢§@¥Î A novel capsaicin derivative VOA induced relaxation in rat mesenteric and aortic arteries: involvement of CGRP, NO, cGMP and endothelium-dependent activities |
97 | Pyrrolo-Benzylisoquinolineªº¦X¦¨¤Î§Ü¦å¤pªO¬¡©Ê±´°Q Antiplatelet Activity of Synthetic Pyrrolo-benzylisoquinolines |
98 | µf´Ô´¹¯Àl¥Íª«VOA¸g¥ÑCGRP, NO, cGMP¤Î¦åºÞ¤º¥Ö¬ÛÃö§@¥Î¤Þ°_¤j¥Õ¹«¸zô½¤°Ê¯ß¤Î¥D°Ê¯ß¤§ÃP¦¢§@¥Î A novel capsaicin derivative VOA induced relaxation in rat mesenteric and aortic arteries: involvement of CGRP, NO, cGMP and endothelium-dependent activities |
99 | Labedipinedilol-A ¹ï©óDOCA-Salt ¤j¹«¤ß«Ç©ÊPKC- ¤Î¤º¤Àªc©Ê°T®§¤§¼vÅT Ventricular PKC- and humoral signaling in DOCA-Salt rats treated with labedipinedilol-A |
100 | Labedipinedilol-A ¹ï©óDOCA-Salt¤j¹«¤ß«Ç©ÊPKC-¤Î¤º¤Àªc©Ê°T®§¤§¼vÅT Ventricular PKC-e and Humoral Signaling in DOCA-Salt Rats Treated with Labedipinedilol-A |
101 | ·s¤@¥N¨ã¦³4-Phenyl Oxypropanolamineªº¤G²BÎMÔr«¬¶tÂ÷¤l³q¹DªýÂ_¾¯§e²{µÇ¤W¸¢¥Ò/¤A«¬¨üÅé«ú§Ü¤Îªø´Á§Ü°ª¦åÀ£ªº ¬¡©Ê The New Generation Dihydropyridine Type Calcium Blockers, Bearing 4-Phenyl Oxypropanolamine, Display alpha-/beta-Adrenoceptor Antagonist and Long Acting Antihypertensive Activities |
102 | ¥ÑHernandia nymphaeifolia ¯Â¤Æ¤§lignans¹ïµÇ¤pºÞ²ÓM¤º¶tÂ÷¤l¤§§@¥Î±´°Q Novel action of lignans isolated from Hernandia nymphaeifoliaon Ca2+ signaling in renal tubular cells |
103 | »§¨ÄõÓi¬°°©¬[ªº¤þ¾JÓil¥Íª«¨ã¦³µÇ¤W¸¢¯À¥Ò/¤A«¬¨üÅéªýÂ_©M¦åºÞÃP¦¢¯S©Ê A Vanillylamide-Based Propanolamine Derivative Displays alpha/beta-Adrenoceptor Blocking and Vasodilating Properties |
104 | KMUP 880708:¤@ºØ¥Hvanillylamide¬[ºcµÇ¤W¸¢¤A¤@«¬¨üÅé«ú§Ü¾¯¨ã¦³¥Ò«¬¨üÅéªýÂ_¤Î¹[Â÷¤l³q¹D¶}±Ò¬¡©Ê KMUP 880708: A Vanyllilamide-Based beta1-Adrenoceptor Antagonist With alpha-Adrenoceptor Blocking and Potassium Channel Opening Activities |
105 | »§¨ÄõÓi¬°°©¬[ªº¤þ¾JÓil¥Íª«¨ã¦³µÇ¤W¸¢¯À¥Ò/¤A«¬¨üÅéªýÂ_©M¦åºÞÃP¦¢¯S©Ê A Vanillylamide-Based Propanolamine Derivative Displays alpha/beta-Adrenoceptor Blocking and Vasodilating Properties |
106 | ¥H¦å¼ß¤¤§¿µµ½è¿Ã¥úÀË´ú»²§U¶EÂ_¤Î°l(9e53)¿ðµo©Ê¥Ö½§µµ½è¯f Detection of plasma uroporphyrin fluorescence as an adjuvant diagnostic and follow-up tool of porphyria cutanea tarda. |
107 | ²Ä¤T¥N¤G²BÏìÔr«¬¶tÂ÷¤lªýÂ_¾¯ Labedipinedilol-B ¨ã¦³¥Ò/¤A«¬µÇ¤W¸¢¿E©ÊªýÂ_¬¡©Ê The Third Generation Dihydropyridine Type Calcium Channel Blocker Labedipinedilol-B displaying £\/£]-Adrenoceptor Blocking Activities |
108 | ²Ä¤T¥N¤G²BÏìÔr«¬¶tÂ÷¤lªýÂ_¾¯ Labedipinedilol-B ¨ã¦³¥Ò/¤A«¬µÇ¤W¸¢¿E©ÊªýÂ_¬¡©Ê The Third Generation Dihydropyridine Type Calcium Channel Blocker Labedipinedilol-B displaying £\/£]-Adrenoceptor Blocking Activities |
109 | Vanidipinedilol: ¤@Ó¥HVanilloid¬°°©¬[¥B¨ã¦³ªýÂ_¶tÂ÷¤l³q¹D¤Î¦åºÞÂX±i¬¡©Ê¤§¤A«¬µÇ¤W¸¢¯À©Ê¨üÅéªýÂ_¾¯ Vanidipinedilol: A Vanilloid-Based beta-Adrenoceptor Blocker Displaying Calcium Entry Blocking and Vasorelaxant Activities |
110 | ¤@ÓîÇ°ò«¬¥Ò/¤A«¬µÇ¤W¸¢¨üÅéªýÂ_¾¯¨ã¦³¦åºÞÃP¦¢¯S©Ê¤§ÃIJz§@¥Î Pharmacological effects of an aldehyde type /-adrenoceptor blocking agent with vasodilating properties |
111 | Labedipinedilol-A:¤@Ó¥HVanilloid¬°°©¬[¨Ã¨ã¦³¶tÂ÷¤l³q¹DªýÂ_¤Îªø®Ä©Ê§Ü°ª¦åÀ£¯S©Ê¤§µÇ¤W¸¢¯À©Ê¥Ò/¤A«¬¨üÅéªýÂ_¾¯ Labedipinedilol-A: A Vanilloid-Based alpha/beta-Adrenoceptor Blocker With Calcium Entry Blocking and Long Acting Anti-hypertensive Properties |
112 | ¤@ÓîÇ°ò«¬¥Ò/¤A«¬µÇ¤W¸¢¨üÅéªýÂ_¨ã¦³¦åºÞÃP¦¢¯S©Ê¤§ÃIJz§@¥Î Pharmacological effects of an aldehyde type/-adrenoceptor blocking agent with vasodilating properties |
113 | ¹[Â÷¤l¬ÛÃöÃĪ«¹ïà®201¶i¤J¥®¹«¤ß¦Ù°ö¾i²ÓMªº¼vÅT--ªì¨B³ø§i The interference of uptake of thallium 201 in cultured rat myocardial cells with existence of potassium related pharmaceuticals - A prelliminary report. |
114 | ¤@ÓîÇ°ò«¬¥Ò/¤A«¬µÇ¤W¸¢¨üÅéªýÂ_¾¯¨ã¦³¦åºÞÃP¦¢¯S©Ê¤§ÃIJz§@¥Î Pharmacological effects of an aldehyde typw/-adrenoceptor blocking agent with vasodilating properties |
115 | Ferulidilol:ݨ㦳¤A¤G«¬µÇ¤W¸¢¿E©ÊP®Ä¾¯§@¥Î¤§¦åºÞÃP¦¢¤Î§Ü®ñ¤Æ§@¥Î¤§µÇ¤W¸¢¿E©Ê¤Î¶tÂ÷¤l³q¹DªýÂ_¾¯ Ferulidilol: A vasodilatory and antioxidant adrenoceptor and calcium entry blocker, with ancillary b2-agonist activity |
116 | µv°ò¤Æ¿»´Ô´¹¯À«·s¦Ò¶q²B½è¤l»Ä©ó¿»´Ô´¹¯À»¤µo¤§·Pı¯«¸g¬¡©Ê¤§¨¤¦â Nitrated nonivamide displaying a drawback of proton¡¦s role in capsaicin associated sensory and neuronal activities |
117 | Ionic effects of capsinolol, a calcitonin gene-related peptide releasing b-adrenoceptor blocker, on isolated cardiac muscle |
118 | Capsazocaine : a capsaicin-sensitivity functional antagonist displays an argument on sensory capsaicin receptor «Ý¸É |
119 | Capsinolol: the first £]-adrenoceptor blocker with an associated calcitonin gene-related peptide releasing activity in the heart |
120 | Comparative study on the pharmacokinetic bioequivalence of two intravascular ceftriazone preparations |
Project
NO |
YEAR ¡X Source ¡X No ¡X Type
Project Name
|
Duration |
---|---|---|
1 |
114 ¡X N °ê¬ì·|(ì¬ì§Þ³¡) ¡X NSTC112-2320-B-037-019-MY3 ¡X 1 Ó¤H«¬
±´°Q¸É°©¯×¹ç¥Î©ó¤ú©Pª¢©M°±¸g«á°©½è²¨ÃPÅj¾¦°Êª«¼Ò«¬¹ïµoª¢©Ê°©·lÃa©M»k°©²ÓM¹L«×¬¡¤Æ¤§ªvÀø¾¯(3/3)( )
|
2025/08/01 ~ 2026/07/31 |
2 |
113 ¡X N °ê¬ì·|(ì¬ì§Þ³¡) ¡X NSTC112-2320-B-037-019-MY3 ¡X 1 Ó¤H«¬
±´°Q¸É°©¯×¹ç¥Î©ó¤ú©Pª¢©M°±¸g«á°©½è²¨ÃPÅj¾¦°Êª«¼Ò«¬¹ïµoª¢©Ê°©·lÃa©M»k°©²ÓM¹L«×¬¡¤Æ¤§ªvÀø¾¯(2/3)( )
|
2024/08/01 ~ 2026/07/31 |
3 |
113 ¡X Z ¤j±M¾Ç¥Í¬ã¨spµe¤Î³Õ¤h«á ¡X NSTC113-2811-B-037-008 ¡X 9 ³Õ¤h«á¬ã¨sû
³Õ¤h¯Å¬ã¨s¤Hû--¶À¤W®¦( )
|
2024/08/01 ~ 2025/07/31 |
4 |
112 ¡X DK «e¤«ÂI(ì®Õ°|) ¡X KMU-DK(A)113001 ¡X
¥Ì¯ó¯Àl¥Íª«ªº§Üµoª¢©M§Ü»k°©²ÓM·s¥Í§@¥Î¥i´î½w¹êÅç©Ê¤ú©Pª¢¤§¬ã¨s( )
|
2024/01/01 ~ 2024/12/31 |
5 |
112 ¡X N °ê¬ì·|(ì¬ì§Þ³¡) ¡X NSTC112-2320-B-037-019-MY3 ¡X 1 Ó¤H«¬
±´°Q¸É°©¯×¹ç¥Î©ó¤ú©Pª¢©M°±¸g«á°©½è²¨ÃPÅj¾¦°Êª«¼Ò«¬¹ïµoª¢©Ê°©·lÃa©M»k°©²ÓM¹L«×¬¡¤Æ¤§ªvÀø¾¯(1/3)( )
|
2023/08/01 ~ 2026/07/31 |
6 |
112 ¡X X °ª©_¦X§@pµe ¡X 113CM-KMU-09 ¡X
±´°Q¶À»G×ô©M¨~ªG苷¥Î©óµÇ°IºÜ¤Þ°_¤§°Ê¯ßµ°ª¬µw¤Æ¤j¹«ªºªvÀø®ÄªG( )
|
2024/08/01 ~ 2025/07/31 |
7 |
112 ¡X Z ¤j±M¾Ç¥Í¬ã¨spµe¤Î³Õ¤h«á ¡X NSTC112-2811-B-037-006 ¡X 9 ³Õ¤h«á¬ã¨sû
³Õ¤h¯Å¬ã¨s¤Hû--¶À¤W®¦( )
|
2023/08/01 ~ 2024/07/31 |
8 |
112 ¡X Z ¤j±M¾Ç¥Í¬ã¨spµe¤Î³Õ¤h«á ¡X NSTC113-2813-C-037-078-B ¡X 8 ¤j±M¾Ç¥Í¬ã¨spµe
113¦~«×¤j±M¾Ç¥Í¬ã¨spµe-Áú©û¿o(Âå¾Ç2)( )
|
2024/07/01 ~ 2025/02/28 |
9 |
111 ¡X DK «e¤«ÂI(ì®Õ°|) ¡X KMU-DK(A)112010 ¡X 1 Ó¤H«¬
±´°Q¯ùÆPl¥Íª«´î½w¹êÅç©ÊÃö¸`ª¢ªº¤À¤l¾÷Âà¬ã¨s( )
|
2023/01/01 ~ 2023/12/31 |
10 |
111 ¡X N °ê¬ì·|(ì¬ì§Þ³¡) ¡X MOST109-2320-B-037-024-MY3 ¡X 1 Ó¤H«¬
±´°Q¯ùÆPl¥Íª«§í¨î¯}°©²ÓM¥Í¦¨©M¤ú©Pª¢¤Þ°_ªº¤ú¼Ñ°©¯}ÃaªºªvÀø¾÷Âà(3/3)( )
|
2022/08/01 ~ 2023/07/31 |
11 |
111 ¡X Z ¤j±M¾Ç¥Í¬ã¨spµe¤Î³Õ¤h«á ¡X NSTC112-2813-C-037-059-B ¡X 8 ¤j±M¾Ç¥Í¬ã¨spµe
112¦~«×¤j±M¾Ç¥Í¬ã¨spµe-¹ùͺ´ü(Å@²z3)( )
|
2023/07/01 ~ 2024/02/29 |
12 |
110 ¡X N °ê¬ì·|(ì¬ì§Þ³¡) ¡X MOST109-2320-B-037-024-MY3 ¡X 1 Ó¤H«¬
±´°Q¯ùÆPl¥Íª«§í¨î¯}°©²ÓM¥Í¦¨©M¤ú©Pª¢¤Þ°_ªº¤ú¼Ñ°©¯}ÃaªºªvÀø¾÷Âà(2/3)( )
|
2021/08/01 ~ 2023/07/31 |
13 |
110 ¡X Z ¤j±M¾Ç¥Í¬ã¨spµe¤Î³Õ¤h«á ¡X MOST111-2813-C-037-062-B ¡X 8 ¤j±M¾Ç¥Í¬ã¨spµe
111¦~«×¤j±M¾Ç¥Í¬ã¨spµe-ªLªÛ¼Ö(Âå¾Ç2)( )
|
2022/07/01 ~ 2023/02/28 |
14 |
109 ¡X DK «e¤«ÂI(ì®Õ°|) ¡X KMU-DK(A)110002 ¡X
±´°Qºd¤¯²y³J¥Õ´î½w¦åºÞ¶t¤Æ¯fÅܪº«OÅ@¾÷Âà( )
|
2021/01/01 ~ 2021/12/31 |
15 |
109 ¡X N °ê¬ì·|(ì¬ì§Þ³¡) ¡X MOST109-2320-B-037-024-MY3 ¡X 1 Ó¤H«¬
±´°Q¯ùÆPl¥Íª«§í¨î¯}°©²ÓM¥Í¦¨©M¤ú©Pª¢¤Þ°_ªº¤ú¼Ñ°©¯}ÃaªºªvÀø¾÷Âà(1/3)( )
|
2020/08/01 ~ 2023/07/31 |
16 |
108 ¡X N °ê¬ì·|(ì¬ì§Þ³¡) ¡X MOST106-2320-B-037-010-MY3 ¡X 1 Ó¤H«¬
¶ÀÍÁ¯À¤ÎÃþ¦üª«¹ï¸¡¥D°Ê¯ß½F©Mµ°ª¬°Ê¯ßµw¤Æ½Õ¸`²É¸¢Åé°ÊºA©M¦Û¾½§@¥Îªº¾÷Âà±´°Q(3/3)( )
|
2019/08/01 ~ 2020/07/31 |
17 |
108 ¡X X °ª©_¦X§@pµe ¡X 109CM-KMU-11 ¡X
±´°Q¶ÀÍÁ¯À¹ï©óºû¥Í¯ÀD3¥[¥§¥j¤B¤Þ°_¤ß¦åºÞ¶t¤Æªº«OÅ@¾÷Âà( )
|
2020/05/01 ~ 2021/04/30 |
18 |
108 ¡X Z ¤j±M¾Ç¥Í¬ã¨spµe¤Î³Õ¤h«á ¡X MOST109-2813-C-037-019-B ¡X 8 ¤j±M¾Ç¥Í¬ã¨spµe
109¦~«×¤j±M¾Ç¥Í¬ã¨spµe-³¯¤ªªé(Âå¾Ç2)( )
|
2020/07/01 ~ 2021/02/28 |
19 |
107 ¡X N °ê¬ì·|(ì¬ì§Þ³¡) ¡X MOST106-2320-B-037-010-MY3 ¡X 1 Ó¤H«¬
¶ÀÍÁ¯À¤ÎÃþ¦üª«¹ï¸¡¥D°Ê¯ß½F©Mµ°ª¬°Ê¯ßµw¤Æ½Õ¸`²É¸¢Åé°ÊºA©M¦Û¾½§@¥Îªº¾÷Âà±´°Q(2/3)( )
|
2018/08/01 ~ 2020/07/31 |
20 |
107 ¡X Y °ªÂå-¹ü°ò¦X§@pµe ¡X 108-CCH-KMU-009 ¡X 1 Ó¤H«¬
±´°Q¯ùÆPl¥Íª«½w¸Ñ¤ßŦ¯Ê¦å©Ò²£¥Íªº¤ßŦ²ÓMä¤`¤§¬ã¨s( )
|
2019/01/01 ~ 2019/12/31 |
21 |
106 ¡X N °ê¬ì·|(ì¬ì§Þ³¡) ¡X MOST106-2320-B-037-010-MY3 ¡X 1 Ó¤H«¬
¶ÀÍÁ¯À¤ÎÃþ¦üª«¹ï¸¡¥D°Ê¯ß½F©Mµ°ª¬°Ê¯ßµw¤Æ½Õ¸`²É¸¢Åé°ÊºA©M¦Û¾½§@¥Îªº¾÷Âà±´°Q(1/3)( )
|
2017/08/01 ~ 2020/07/31 |
22 |
105 ¡X Z ¤j±M¾Ç¥Í¬ã¨spµe¤Î³Õ¤h«á ¡X MOST106-2813-C-037-023-B ¡X 8 ¤j±M¾Ç¥Í¬ã¨spµe
106¦~«×¤j±M¾Ç¥Í¬ã¨spµe-±i¤¨ºö(¥Í§Þ3)( )
|
2017/07/01 ~ 2018/02/28 |
23 |
104 ¡X N °ê¬ì·|(ì¬ì§Þ³¡) ¡X NSC102-2320-B-037-028-MY3 ¡X 1 Ó¤H«¬
±´°Q¯ùÆPl¥Íª«»¤¾É¤ß¦Ù²ÓM¦ÛÅé§]¾½¦æ¬°¤§¤ßŦ«OÅ@¾÷Âà(3/3)( )
|
2015/08/01 ~ 2016/07/31 |
24 |
104 ¡X TP ³»¦ypµe(°ªÂå) ¡X KMU-TP104PR03 ¡X
±´°Q³F´ß¯ó¡B¨®®á¤l©M¥ÕTµÑ¨úª«½Æ¤è¤§§Ü°ª¦åÀ£¤Î¤ßŦ«OÅ@§@¥Î¾÷Âà( )
|
2015/11/01 ~ 2016/09/30 |
25 |
104 ¡X X °ª©_¦X§@pµe ¡X 105CM-KMU-07 ¡X
±´°Q¶ÀÍÁ¯À§í¨î¦åºÞ¦¬ÁY¯ÀII»¤¾É¸¡¥D°Ê¯ß½Fªº¤À¤l¾÷Âà( )
|
2016/05/01 ~ 2017/04/30 |
26 |
103 ¡X N °ê¬ì·|(ì¬ì§Þ³¡) ¡X NSC102-2320-B-037-028-MY3 ¡X 1 Ó¤H«¬
±´°Q¯ùÆPl¥Íª«»¤¾É¤ß¦Ù²ÓM¦ÛÅé§]¾½¦æ¬°¤§¤ßŦ«OÅ@¾÷Âà(2/3)( )
|
2014/08/01 ~ 2016/07/31 |
27 |
103 ¡X X °ª©_¦X§@pµe ¡X 104CMKMU010 ¡X
±´°Q²ÓM¥~¼öªL§J³J¥Õ§í¨î¥Ñ¯×¦hÁÞÅé¨ë¿E¤§¥¨¾½²ÓMµoª¢¤ÏÀ³ªº§@¥Î¾÷Âà( )
|
2015/05/01 ~ 2016/04/30 |
28 |
102 ¡X N °ê¬ì·|(ì¬ì§Þ³¡) ¡X NSC102-2320-B-037-028-MY3 ¡X 1 Ó¤H«¬
±´°Q¯ùÆPl¥Íª«»¤¾É¤ß¦Ù²ÓM¦ÛÅé§]¾½¦æ¬°¤§¤ßŦ«OÅ@¾÷Âà(1/3)( )
|
2013/08/01 ~ 2016/07/31 |
29 |
101 ¡X N °ê¬ì·|(ì¬ì§Þ³¡) ¡X NSC99-2320-B-037-015-MY3 ¡X 1 Ó¤H«¬
±´°QÁC»Ä¤Gà酶§í¨î¾¯¹ï»k°©²ÓM·s¥Í§@¥Î¤§¤À¤l½Õ±±¾÷¨î(3/3)( )
|
2012/08/01 ~ 2013/07/31 |
30 |
100 ¡X N °ê¬ì·|(ì¬ì§Þ³¡) ¡X NSC99-2320-B-037-015-MY3 ¡X 1 Ó¤H«¬
±´°QÁC»Ä¤Gà酶§í¨î¾¯¹ï»k°©²ÓM·s¥Í§@¥Î¤§¤À¤l½Õ±±¾÷¨î(2/3)( )
|
2011/08/01 ~ 2013/07/31 |
31 |
099 ¡X N °ê¬ì·|(ì¬ì§Þ³¡) ¡X NSC99-2320-B-037-015-MY3 ¡X 1 Ó¤H«¬
±´°QÁC»Ä¤Gà酶§í¨î¾¯¹ï»k°©²ÓM·s¥Í§@¥Î¤§¤À¤l½Õ±±¾÷¨î(1/3)( )
|
2010/08/01 ~ 2013/07/31 |
32 |
098 ¡X N °ê¬ì·|(ì¬ì§Þ³¡) ¡X NSC96-2628-B-037-008-MY3 ¡X 1 Ó¤H«¬
±´°QRho-kinase§í¨î¾¯¦b¤ß¦Ù±ð¶ë©M¦åºÞµjÅ˩ʤߵ±µh¼Ò¦¡ªº²ÓM«OÅ@¾÷Âà(3/3)( )
|
2009/08/01 ~ 2010/07/31 |
33 |
097 ¡X N °ê¬ì·|(ì¬ì§Þ³¡) ¡X NSC96-2628-B-037-008-MY3 ¡X 1 Ó¤H«¬
±´°QRho-kinase§í¨î¾¯¦b¤ß¦Ù±ð¶ë©M¦åºÞµjÅ˩ʤߵ±µh¼Ò¦¡ªº²ÓM«OÅ@¾÷Âà(2/3)( )
|
2008/08/01 ~ 2010/07/31 |
34 |
096 ¡X N °ê¬ì·|(ì¬ì§Þ³¡) ¡X NSC96-2628-B-037-008-MY3 ¡X 1 Ó¤H«¬
±´°QRho-kinase§í¨î¾¯¦b¤ß¦Ù±ð¶ë©M¦åºÞµjÅ˩ʤߵ±µh¼Ò¦¡ªº²ÓM«OÅ@¾÷Âà(1/3)( )
|
2007/08/01 ~ 2010/07/31 |
35 |
095 ¡X C ¤¤ÂåÃÄ ¡X CCMP 96-RD-014 ¡X 1 Ó¤H«¬
¤T¶ÀÂm¤ß´ö¹ï¤ßŦ¯Ê¦å¦AÄé¬y¶Ë®`°Êª«¼Ò¦¡¤§Àø®Äµû¦ô( )
|
2007/05/01 ~ 2008/04/30 |
36 |
095 ¡X N °ê¬ì·|(ì¬ì§Þ³¡) ¡X NSC95-2320-B-037-041- ¡X 1 Ó¤H«¬
±´°Q²Ä¤T¥NÎMÔr«¬¶tÂ÷¤lªýÂ_¾¯§Ü®ñ¤Æ§C±K«×¯×³J¥Õ¤Þ°_¶Ë®`¤§¨¾¤î°Ê¯ßµ°ª¬µw¤Æ§@¥Î( )
|
2006/08/01 ~ 2007/07/31 |
37 |
094 ¡X N °ê¬ì·|(ì¬ì§Þ³¡) ¡X NSC94-2320-B-037-042- ¡X 1 Ó¤H«¬
±´°QÎMÔr«¬¶tÂ÷¤l³q¹DªýÂ_¾¯§í¨î¦åºÞ·l¶Ë«á¤º¼h¼W¥Í²{¶H¤§¦åºÞ«OÅ@¾÷Âà( )
|
2005/08/01 ~ 2006/07/31 |
38 |
093 ¡X N °ê¬ì·|(ì¬ì§Þ³¡) ¡X NSC93-2320-B-037-036- ¡X 1 Ó¤H«¬
±´°QÎMÔr«¬¶tÂ÷¤lªýÂ_¾¯§Ü¤º¥Ö²ÓM®ñ¤Æ¶Ë®`¤§¦åºÞ«OÅ@§@¥Î( )
|
2004/08/01 ~ 2005/07/31 |
39 |
092 ¡X N °ê¬ì·|(ì¬ì§Þ³¡) ¡X NSC92-2320-B-037-024- ¡X 1 Ó¤H«¬
²Ä¤T¥NÎMÔr«¬¶tÂ÷¤l³q¹DªýÂ_¾¯¦b¦åºÞ¥·Æ¦Ù¤Î¤º¥Ö²ÓM¤§¦åºÞ«OÅ@§@¥Î¾÷Âà±´°Q( )
|
2003/08/01 ~ 2004/07/31 |
40 |
091 ¡X N °ê¬ì·|(ì¬ì§Þ³¡) ¡X NSC91-2320-B-037-062 ¡X 1 Ó¤H«¬
²Ä¤T¥NÎMÔr«¬¶tÂ÷¤l³q¹DªýÂ_¾¯§Ü¯Ê¦å¦AÄé¬y¶Ë®`¤§¤À¤l¾÷Âà±´°Q( )
|
2002/08/01 ~ 2003/07/31 |
41 |
090 ¡X N °ê¬ì·|(ì¬ì§Þ³¡) ¡X NSC90-2315-B-037-001 ¡X 1 Ó¤H«¬
±´°Q²Ä¤T¥NÎMÔr«¬¶tÂ÷¤l³q¹DªýÂ_¾¯¹ï¤ßŦ¯Ê¦å¦AÄé¬y¶Ë®`¤§«OÅ@§@¥Î(Cardiopective effect of the third generation dihydropy-ridine type calcium chennel blockers on myocardial ischemia/reperfusion in jury)
|
2001/08/01 ~ 2002/07/31 |
42 |
089 ¡X N °ê¬ì·|(ì¬ì§Þ³¡) ¡X NSC 89-2320-B-037-082- ¡X 1 Ó¤H«¬
¨ã¹[³q¹D§í¨î©Ê½èªºµÇ¤W¸¢¯À©Ê¨üÅé¥Ò/¤A«¬ªýÂ_¾¯¤§ÃIJz±´°Q(Pharmacological approach of novel type alpha/beta-adrenocep-tor blocker with potassium channel blocking properties)
|
2000/08/01 ~ 2001/07/31 |
43 |
088 ¡X N °ê¬ì·|(ì¬ì§Þ³¡) ¡X NSC 89-2320-B-037-003- ¡X 1 Ó¤H«¬
¨ã¹[³q¹D§í¨î©Ê½èªºµÇ¤W¸¢¯À©Ê¨üÅé¥Ò/¤A«¬ªýÂ_¾¯¤§ÃIJz±´°Q(1/3)(Pharmacological approach of novel type alpha/beta-adrenocep-tor blocker with potassium channel blocking properties)
|
1999/08/01 ~ 2000/07/31 |
44 |
087 ¡X N °ê¬ì·|(ì¬ì§Þ³¡) ¡X NSC88-2314-B-037-010- ¡X 1 Ó¤H«¬
±´°Q·s«¬¨ã¦³CGRPÄÀ¥X§@¥Î¤§¥Ò/¤A«¬µÇ¤W¸¢¯À©Ê¨üÅéªýÂ_¾¯(Studies on novel alpha- and beta-adrenoceptor blockeer with an associated calcitonin gene-related peptide releasing activity)
|
1998/08/01 ~ 1999/07/31 |
45 |
086 ¡X N °ê¬ì·|(ì¬ì§Þ³¡) ¡X NSC87-2314-B037-098 ¡X
CAPSINOLOL¦b°Æ¥æ·P¯«¸g¶Ç¤J¤Î¶Ç¥X³~®|¤§ÃIJz¯S©Ê(Pharmacological characteristics of capsinolol in the parasympathetic afferent and efferent pathways)
|
1997/08/01 ~ 1998/07/31 |
Patent
NO | Patent Name | Country | Certified Date | Patent No |
---|---|---|---|---|
1 | ¯ùÆP¤Æ¦Xª«¤§§í¨î°©½è²¨ÃP¯g¬¡©Ê | ¤¤µØ¥Á°ê | 2013/06/21 | I399205 |
2 | ¯ùÆP¤Æ¦Xª«¤§§í¨î°©½è²¨ÃP¯g¬¡©Ê | ¬ü°ê | 2013/08/13 | 8,507,506 |
3 | ¤@ºØTMD1³J¥Õ½è¥Î©ó»s³Æµoª¢©Ê°©¬y¥¢ÃĪ«ªº¥Î³~ | ¬ü°ê | 2017/10/03 | 9,775,885 |
4 | TMD1 ³J¥Õ¥Î©óªv?°©½è?¥¢¯e¯f | ¤¤µØ¥Á°ê | 2019/02/11 | I650135 |